Wells Fargo analyst Cerena Chen initiated coverage of Zealand Pharma (ZLDPF) with an Overweight rating and DKK 650 price target The firm says Zealand is poised to become a key obesity player with petrelintide and survodutide, differentiated assets in emerging amylin and GLP-1/glucagon drug classes. The first half of 2026 readouts for both in obesity should unlock potential for greater than $4B combined peak revenue opportunity, Wells adds.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma’s Petrelintide Trial: A Potential Game-Changer in Obesity Treatment?
- Zealand Pharma initiated with an Overweight at Barclays
- Zealand Pharma initiated with an Outperform at BNP Paribas Exane
- Zealand Pharma price target lowered to DKK 850 from DKK 1,050 at Berenberg
- Zealand Pharma announces results from 28-week Phase 1b trial of dapiglutide